136610-11-2

Upstream product

• 60512-57-4 1-(2,2-dibromovinyl)-4-methoxybenzene 
• 74189-56-3 4-(tetrahydropyran-2-yloxy)benzaldehyde 
• 123-11-5 4-methoxy-benzaldehyde 
• 78589-65-8 3-(4-hydroxyphenyl)prop-2-yn-1-oic acid 
• 144256-13-3 1,1-dibromo-2-(4-hydroxyphenyl)ethylene 
• 70987-78-9 (S)-Glycidyl tosylate 
• 136634-54-3 methyl (4-hydroxyphenyl)propynoate 
• 119754-16-4 [4-(tetrahydropyran-2-yloxy)phenyl]ethyne 

Downstream Products

• 136610-12-3 [4-(2-Hydroxy-3-{2-[(morpholine-4-carbonyl)-amino]-ethylamino}-propoxy)-phenyl]-propynoic acid methyl ester 
• 136610-14-5 [4-((S)-2-Hydroxy-3-{2-[(morpholine-4-carbonyl)-amino]-ethylamino}-propoxy)-phenyl]-propynoic acid methyl ester 

Relevant academic research and scientific papers

Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101

A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.